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Abstract
We aimed to evaluate the association between statin use and cognitive function.
Cognitive function was measured with the Ruff Figural Fluency Test (RFFT; worst
score, 0; best score, 175 points) and the Visual Association Test (VAT; low
performance, 0–10; high performance, 11–12 points) in an observational study that
included 4,095 community-dwelling participants aged 35–82 years. Data on statin
use were obtained from a computerized pharmacy database. Analysis were done
for the total cohort and subsamples matched on cardiovascular risk (N51232) or
propensity score for statin use (N53609). We found that a total of 904 participants
(10%) used a statin. Statin users were older than non-users: mean age (SD) 61 (10)
vs. 52 (11) years (p,0.001). The median duration of statin use was 3.8
(interquartile range, 1.6–4.5) years. Unadjusted, statin users had worse cognitive
performance than non-users. The mean RFFT score (SD) in statin users and non-
users was 58 (23) and 72 (26) points, respectively (p,0.001). VAT performance
was high in 261 (29%) statin users and 1351 (43%) non-users (p,0.001). However,
multiple regression analysis did not show a significant association of RFFT score
with statin use (B, 20.82; 95%CI, 22.77 to 1.14; p50.41) nor with statin solubility,
statin dose or duration of statin use. Statin users with high doses or long-term use
had similar cognitive performance as non-users. This was found in persons with low
as well as high cardiovascular risk, and in younger as well as older subjects. Also,
the mean RFFTscore per quintile of propensity score for statin use was comparable
for statin users and non-users. Similar results were found for the VAT score as
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outcome measure. In conclusion, statin use was not associated with cognitive
function. This was independent of statin dose or duration of statin use.
Introduction
Cardiovascular risk factors are not only associated with coronary heart disease and
stroke but also with cognitive dysfunction, due to shared atherosclerotic
complications [1–3]. As dyslipidemia is a major cardiovascular risk factor, it is not
surprising that dyslipidemia in midlife associates with cognitive dysfunction and
dementia in later life [4–6]. Dyslipidemia can be effectively improved by statins.
Therefore, it can be hypothesized that statin use has beneficial effects on cognitive
function.
Up till now, two randomized controlled trials (RCTs) have studied the effect of
statin use on cognitive function and both failed to show a beneficial effect [7, 8].
One explanation could be the relatively short duration of these RCTs. Possibly,
statins need a longer period to have a positive effect on cognitive function.
Notably, several observational studies that had a longer duration of follow-up
than these RCTs suggested a favorable effect [9–16]. For example, elderly with.4
years of continuous statin use had less cognitive decline than subjects who used
statins less intensively [12]. In line with these data a recent meta-analysis found no
short-term effects on cognitive function, whereas long-term use might be
associated with a beneficial role in the prevention of dementia [17]. Duration of
statin use might thus influence results [18], and this should formally be tested.
Due to the financial burden, RCTs of longer duration probably are not feasible.
Therefore, long-term observational studies are necessary to evaluate whether long-
term statin use prevents cognitive decline [19]. However, confounding by
indication can be an important limitation of observational studies as, generally,
statin users have a different cardiovascular risk profile than non-users, and this
type of bias needs to be addressed.
The aim of this observational study was to evaluate the association between
statin use and cognitive function in a large community-based population aged 35–
82 years with.10 year follow-up data on statin use, and to study whether
duration of treatment influences this association. All participants underwent a




This study was part of the third survey of the Prevention of REnal and Vascular
ENd-stage Disease (PREVEND) cohort study. The PREVEND study is a
prospective cohort study investigating the natural course of increased albuminuria
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and its association with renal and cardiovascular disease [20, 21]. In brief, at
baseline, 8,592 participants aged 28–75 years were selected from inhabitants of the
city of Groningen (The Netherlands) based on their urinary albumin excretion
(UAE): 2,592 with UAE,10 mg/L and 6,000 with UAE$10 mg/L. These
participants completed the baseline survey in 1997–1998 and were followed over
time. A total of 6,894 participants (80%) completed the second survey in 2001–
2003, and 5,862 (68%) the third survey in 2003–2006. All surveys included
assessment of demographic characteristics, cardiovascular risk factors and
haematological and biochemical parameters. In the third survey, measurement of
cognitive function was added to the study protocol.
Standard protocol approvals and participant consents
All participants gave written informed consent. The PREVEND study was
approved by the medical ethics committee (METc) of University Medical Center
Groningen and conducted in accordance with the guidelines of the Helsinki
declaration.
Cognitive function
The RFFT was the primary outcome measure for cognitive function [22–24]. In
brief, the RFFT requires participants to draw as many unique designs as possible
within a set time limit by connecting dots in a different pattern while avoiding
repetitions of designs. The RFFT is generally seen as a measure of executive
function [22, 23, 25]. The main outcome measure of the RFFT is the total number
of unique designs. The lowest (worst) RFFT score is 0 points, the highest (best)
score is 175 points [22, 23]. Each RFFT was scored by two trained and
independent examiners.
The VAT was used as a secondary outcome measure for cognitive function. The
VAT is a brief learning task that is designed to detect impaired memory, including
anterograde amnesia [26]. The test consists of six drawings of pairs of interacting
objects. The participant needs to name each object and, later, is presented with
one object from the pair and asked to name the other. The lowest (worst) score is
0 points and the highest (best) score is 12 points [26].
Statin use
Subject-specific information on statin use was obtained from IADB.nl, a database
comprising pharmacy-dispensing data from all community pharmacies in the city
of Groningen, The Netherlands, since 1999 [27]. These data include information
on the name of the drug dispensed, Anatomical Therapeutical Chemical (ATC)
classification, solubility (hydrophilic or lipophilic), date of prescription, number
of days the drug was prescribed and the number of prescribed defined daily doses
(DDD). DDD is defined by the WHO as the drug units representing dosages with
approximately similar efficacy. One DDD corresponds to the following dosage for
A Long-Term Observational Study on Statin Use and Cognitive Function
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each statin respectively: Simvastatin 30 mg, Pravastatin 30 mg, Fluvastatin 60 mg,
Atorvastatin 20 mg and Rosuvastatin 10 mg.
Statin use was defined as at least one prescription in the period preceding the
third survey of the PREVEND study with at least one prescription #100 days
before performance of the cognitive function tests. Statin use was not only defined
dichotomously (yes/no), but also explored by statin solubility, daily dose (defined
as the mean amount of DDDs per day), duration of use (years) and cumulative
dose over time (overall amount of DDDs used).
Other variables
Educational level was classified by highest achieved degree based on a
questionnaire and divided into four groups: Primary school level, 0–8 years of
education; lower secondary level, 9–12 years; higher secondary level, 13–15 years;
university level, $16 years. A history of cardiovascular events was defined as a
prior cardiac, cerebrovascular or peripheral vascular event requiring hospitaliza-
tion. Past medical history was derived from a questionnaire at baseline and the
Dutch national registry of hospital discharge diagnoses during follow-up. Diabetes
mellitus (DM) was defined as a fasting glucose $7 mmol/L, a non-fasting glucose
$11.1 mmol/L or the use of glucose-lowering drugs. Hypertension was defined as
use of antihypertensive drugs or systolic blood pressure.140 mmHg or diastolic
blood pressure.90 mmHg. Albuminuria was calculated from the mean of two
24-h urinary collections and elevated albuminuria was defined as $30 mg/24 h.
Matching
For the specific aim of this study, we created three additional (partly overlapping)
subsamples from the total study population (Fig. 1): 1. a subsample of statin users
and non-users who were matched one-to-one on age, sex and educational level; 2.
a subsample of statin users and non-users who were matched one-to-one on
cardiovascular risk profile; 3. a subsample of statin users and non-users who were
compared by quintile of propensity score for statin use.
Cardiovascular risk
Overall cardiovascular risk was measured by the Framingham risk score for
general cardiovascular disease (FRS) [28], a composite measure designed to
predict the risk of developing a cardiovascular event within the next ten years.
Calculation of the FRS is based on age, sex, DM, current smoker status, SBP, total
cholesterol, HDL-cholesterol and use of blood pressure lowering agents. A higher
FRS is associated with a higher risk of a new cardiovascular event: the lowest score
is 25 (risk ,1%) and the highest score 33 (risk.30%) [28].
A Long-Term Observational Study on Statin Use and Cognitive Function
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Propensity score
A propensity score balances covariates in observational studies associated with the
prescription of drugs and is used to reduce bias by indication in non-randomized
studies. In this study, the propensity score for statin therapy was calculated by a
Fig. 1. Flow diagram of the selection of the study population.
doi:10.1371/journal.pone.0115755.g001
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logistic regression model including age, sex, educational level, history of CVD,
smoking, DM, hypertension, BMI and albuminuria [29].
Statistical analysis
Statistical analysis was performed with IBM SPSS Statistics version 20 (IBM
Corporation, Amonk, NY). Normally distributed data are presented as mean and
standard deviation (SD) and skewed data as median and interquartile range
(IQR). Differences between two samples were tested by t-test or, if appropriate,
Mann-Whitney U test. Differences between more than 2 samples were tested by
ANOVA. Adjusted RFFT scores were calculated by analysis of covariance
(ANCOVA). Adjustment was made for age, sex, educational level, history of CVD,
DM, hypertension, BMI, smoking, alcohol use, lipid levels, family history of CVD
and propensity score.
Multiple linear regression models
Multiple linear regression analysis was used to model the independent association
of RFFT score with statin use. In all regression models, RFFT score was the
dependent variable, and a measure of statin use was the independent variable
(statin use (yes/no), statin solubility, cumulative statin dose, duration of statin
use, or mean daily dose). The regression models were adjusted for three different
sets of possible confounders: model 1, adjusted for age, sex and educational level;
model 2, adjusted for the covariates of model 1 plus DM, hypertension, history of
CVD, smoking, BMI, albuminuria and lipid levels. To avoid overcorrection the
propensity score was not included as a covariate in any of the regression models
on top of the single covariates (which were also used to calculate the propensity
score).
Similar analyses were performed for VAT score as the cognitive outcome
measure. Because of its skewed distribution, the VAT score was dichotomized at
the median into low performance (#10 points) and high performance ($11
points). Accordingly, the association of VAT performance with statin use was
evaluated by logistic regression analysis (see above).
Because the PREVEND cohort is enriched for subjects with higher levels of
albuminuria which may be negatively associated with cognitive function [30],
analyses were repeated in a subsample of the PREVEND cohort which is
representative for the general population (prevalence of elevated albuminuria
8%).
Results
All 5,862 participants of the third survey were reviewed. Subjects with no or
incomplete data on cognitive function (n51704), statin use or other main
variables (n563) were excluded (Fig. 1). The final overall study population thus
comprised 4095 subjects.
A Long-Term Observational Study on Statin Use and Cognitive Function
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The three (partly overlapping) subsamples from the final study population
(Fig. 1) consisted of 1808 statin users and non-users matched on age, sex and
educational level (subsample 1), 1232 statin users and non-users matched on
cardiovascular risk (subsample 2), and 3609 of statin users and non-users who
could be compared by quintile of propensity score for statin use (subsample 3).
Statin use
Ten percent (n5904) of the final study population used statins. Statin users and
non-users were equally represented among participants with complete and
incomplete (or no) cognitive data (20.7% versus 19.8% respectively). The median
duration of statin use was 3.8 (interquartile range, 1.6–4.5) years. Mean (SD) daily
dose was 1.7 (0.7) DDDs per day and median [IQR] cumulative dose over time
was 2000 [90 to 5376] DDDs. Statin users were older and more often male than
non-users (Table 1). Their educational level was also lower. In addition, statin
user had lower performance on the cognitive tests than non-users: their mean
RFFT score (SD) was lower than in non-users (58 (23) points vs. 72 (26) points; P
,0.001), as was their percentage with high performance on the VAT (29% vs
43%; P,0.001). Statin users also had higher overall cardiovascular risk profile
scores (FRS) and higher prevalence rates of individual cardiovascular risk factors
(except for smoking) than non-users (Table 1).
RFFT score and statin use
Unadjusted, statin users had worse cognitive performance than non-users. The
mean RFFT score (SD) in statin users and non-users was 58 (23) and 72 (26)
points, respectively (p,0.001). However, RFFT score was not associated with
statin use (yes/no), solubility, mean dose or cumulative dose over time if subjects
were matched on age, sex and educational level. RFFT score was similar among
tertiles of cumulative statin dose (Table 2). Also, there was no association of RFFT
score with duration of statin use (Fig. 2). For every category of duration of use,
statin users had similar RFFT scores as non-users who were matched on age, sex
and educational level. These findings were confirmed by multiple regression
analyses. In none of the models, a statistically significant effect was found for
solubility, mean dose, cumulative dose or duration of statin use (Table 2).
RFFT score was dependent on overall cardiovascular risk and decreased with
increasing FRS (Fig. 3). Mean RFFT score decreased from 67 points in persons
with the lowest FRS to 49 points in persons with the highest FRS. However, in all
FRS categories, statin users and non-users had comparable RFFT scores (Fig. 3).
Similarly, RFFT score was dependent on propensity score for statin use and mean
RFFT scores decreased with increasing propensity score (Table 3). There was
however no difference between statin users and non-users within each quintile of
propensity score.
A Long-Term Observational Study on Statin Use and Cognitive Function
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VAT score and statin use
Unadjusted, statin users had worse cognitive performance than non-users. VAT
performance was high in 261 (29%) statin users and 1351 (43%) non-users
(p,0.001). However, VAT score was not associated with statin use (yes/no),
solubility, mean dose, cumulative dose or duration of statin use over time if
subjects were matched on age, sex and educational level. VAT score was similar
among tertiles of cumulative statin dose (S1 Fig.). Logistic regression analysis in
the overall study population yielded similar results. After correction for age, sex
and educational level the odds ratio for low performance on the VAT was not
significantly lower for statin users (OR 20.146, 95%CI 20.41 to 0.12, P50.284).
Further adjustment did not change results. There was no significant association of
the VAT score with any of the other determinants of statin use (data not shown).
VAT score was also dependent on overall cardiovascular risk and decreased
with increasing FRS. In the total study population the percentage of subjects with
low performance on the VAT score gradually increased from 58% in the group




Age, years, mean (SD) 61 (10) 52 (11) ,0.001
Male, n (%) 593 (65) 1547 (48) ,0.001
Educational level, n (%)
Primary school 136 (15) 263 (8) ,0.001
Lower secondary 357 (40) 855 (27)
Higher secondary 217 (24) 888 (28)
University 194 (21) 1188 (37)
Cardiovascular risk factors
History of vascular events, n (%) 215 (24) 92 (3) ,0.001
Diabetes mellitus, n (%) 174 (19) 81 (3) ,0.001
Hypertension, n (%) 807 (61) 449 (33) ,0.001
Systolic blood pressure, mmHg, mean (SD) 133 (19) 123 (17) ,0.001
Diastolic blood pressure, mmHg, mean (SD) 75 (9) 73 (9) ,0.001
Current smoking, n (%) 225 (25) 747 (24) 0.37
Body Mass Index, kg/m2, mean (SD) 28 (4) 26 (4) ,0.001
HDL cholesterol, mmol/L, mean (SD) 1.3 (0.4) 1.4 (0.4) ,0.001
Non-HDL cholesterol, mmol/L, mean (SD) 4.9 (1.1) 5.5 (1.0) ,0.001
Elevated albuminuria, n (%) 267 (29) 329 (10) ,0.001
Framingham Risk Score,apoints, mean (SD) 14 (5) 10 (6) ,0.001
RFFT score, points, mean (SD) 58 (23) 72 (26) ,0.001
High performance on VAT, n (%) 261 (29) 1351 (43) ,0.001
Abbreviations: FRS, Framingham Risk Score; RFFT, Ruff Figural Fluency Test; SD, standard deviation; VAT, Visual Association Test.
aThe Framingham Risk Score (FRS) for general cardiovascular risk includes age, sex, diabetes mellitus, smoking, treated and untreated blood pressure and
lipid levels [28].
doi:10.1371/journal.pone.0115755.t001
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with the lowest FRS to 74% in the group with the highest FRS (P for trend
,0.001). Within all FRS categories, statin users and non-users had comparable
VAT scores. Similarly, there was no significant difference in VAT score between
statin users and non-users within quintiles of propensity score (data not shown).
Elevated albuminuria was present in 14% of the study group. Various
sensitivity analyses in the subsample of the PREVEND cohort which is
representative for the general population (7.5%) in the different subpopulations
gave essentially similar results.
Table 2. Multiple linear regression analyses of the association of RFFT score with statin use.
Statin exposure Model 1a Model 2b
B 95%CI p-value B 95%CI p-value
Drug use
No statin Ref. Ref.
Statin 22.25 23.86 to 20.63 0.006 20.51 22.28 to 1.26 0.57
Statin type
Hydrophilic Ref. Ref.
Lipophilic +0.41 22.18 to 2.99 0.76 +0.001 22.64 to 2.64 1.0
Cumulative dose, total DDD
Continuous 0.00 20.001 to 0.00 0.095 20.001 20.001 to 0.001 0.98
Categorical
no statin Ref. Ref.
Tertile 1, ,1221 21.99 24.50 to 0.52 0.12 +0.06 22.56 to 2.67 0.97
Tertile 2, 1221–2858 22.39 24.90 to 0.11 0.061 20.80 23.39 to 1.80 0.55
Tertile 3,.2858 22.34 24.84 to 0.15 0.066 20.77 23.38 to 1.83 0.56
Cumulative time exposure, years
Continuous 20.07 20.60 to 0.47 0.81 20.14 20.68 to 0.40 0.61
Categorical
No statin Ref. Ref.
1–2 22.60 25,14 to 20.54 0.05 21.09 23.70 to 1.52 0.42
3–4 22.12 24.57 to 0.18 0.07 21.01 23.43 to 1.41 0.42
5–6 21.52 24.98 to 1.94 0.39 20.13 23.65 to 3.39 0.94
7–8 21.18 25.73 to 3,36 0.61 +0.07 24.53 to 4.67 0.98
.8 24.71 210.77 to 1.24 0.12 23.44 29.43 to 2.54 0.26
Daily dose, mean DDD/day
Continuous 20.98 21.74 to 0.22 0.12 20.19 21.02 to 0.63 0.64
Categorical
no statin Ref. Ref.
low dose, #1.5 21.82 24.24 to 0.60 0.14 20.28 22.80 to 2.25 0.83
high dose,.1.5 22.48 24.38 to 0.58 0.11 20.64 22.68 to 1.40 0.54
Abbreviations: CI, confidence interval; DDD, defined daily dose; DM, diabetes mellitus; Ref., reference category.
aModel 1: adjusted for age, sex and educational level.
bModel 2: adjusted for age, sex, educational level, DM, hypertension, history of cardiovascular disease, smoking, BMI, albuminuria and lipid levels.
doi:10.1371/journal.pone.0115755.t002
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Discussion
In this large cross-sectional study, statin use was not associated with cognitive
function. This was not only found in persons with low cardiovascular risk but also
in persons with high cardiovascular risk, and in younger as well as older subjects.
Even statin users who used high doses of statins or used statins for more than 8
years had a similar cognitive performance as non-users. Thus, it is unlikely that
the lack of effect in previous RCTs was due to the relatively short treatment period
[7, 8].
So far, the underlying mechanisms by which statins might affect cognitive
function are not unraveled. Studies on lipid profile and cognitive function yield
contradictory results. When measured in midlife, high cholesterol levels associate
with an increased risk of late-life dementia and cognitive decline [4, 5]. However,
late-life elevated cholesterol levels are not related to cognitive function, or
inversely related [4, 5, 31–33]. Similarly, studies on statin use and cognitive
function also showed diverting results. Several observational studies demonstrated
that statin users had less cognitive decline or lower risk of developing dementia
doi:10.1371/journal.pone.0115755.g002
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Fig. 2. RFFT score dependent on duration of statin use. Statin users and non-users were matched on age,
sex and educational level. Bars represent theupper limit of the 95% confidence intervals.
[9–16], while others found no differences [34–36]. Moreover, in some positive
studies, the effect of statin use was inconsistent for different statins as well as for
different outcome measures [11, 12, 16]. These contradictory results have been
Fig. 3. RFFT score dependent on cardiovascular risk score as measured by the Framingham Risk
Score. Statin users and non-users were matched on Framingham Risk Score (FRS).28 A higher FRS is
associated with a higher risk of cardiovascular and cerebrovascular events within the forthcoming 10 years.
RFFTscores were only adjusted for education level as age, sex and cardiovascular risk factors are included in
the FRS. Bars represent the upper limit of the 95% confidence intervals.
doi:10.1371/journal.pone.0115755.g003
Table 3. RFFT score in subjects with and without statin use per quintile of propensity score.
Quintile of Propensity Scorea Statin use Number Mean RFFT 95% CI p-value
1 No 785 86.2 84.6 to 87.8 0.55
Yes 30 83.7 76.0 to 91.4
2 No 743 77.8 76.0 to 79.6 0.20
Yes 72 73.9 68.3 to 79.5
3 No 689 67.7 65.9 to 69.5 0.87
Yes 125 67.4 63.3 to 71.5
4 No 591 60.9 59.0 to 62.8 0.20
Yes 223 58.6 55.6 to 61.6
5 No 365 51.5 49.4 to 53.6 0.85
Yes 450 51.7 50.0 to 53.4
aThe propensity score included age, sex, educational level, history of cardiovascular disease, smoking, diabetes mellitus, hypertension, BMI and
albuminuria.
doi:10.1371/journal.pone.0115755.t003
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attributed to various limitations of the studies such as highly selected study
samples (mostly aged $60 years), varying statin types, short treatment durations
or other possible confounders [18]. Although many of these limitations were
overcome in our study, we still did not find a beneficial effect of statins of
cognitive function.
Despite plausible neuroprotective benefits of statins through improved
cholesterol metabolism, stroke reduction and pleiotropic effects (e.g. improving
endothelial function, inhibiting oxidative stress) evidence for sustained cognitive
benefit is restricted. In general, neurodegenerative pathologies probably have
multifactorial determinants which separately add to (the severity of) cognitive
impairment [37, 38]. It could be hypothesized that among these multifactorial
determinants, the effect of statins may be too small to make a difference in
cognitive function.
Strengths and Limitations
Some limitations of this study must be acknowledged. At first, the design of this
study does not formally allow a conclusion on a causal relationship between
variables. Second, an inherent limitation of any observational analysis includes
indication bias. In our study this includes the initiation of statin treatment in
people with increased cardiovascular risk. By creating subgroups of statin users
and non-users with comparable cardiovascular risk profile and subgroups with
comparable propensity score for statin use we aimed to minimize this bias. We do
not assume any bias induced by selective drop-out of (non) statin users who
refused cognitive testing, as statin users and non-users were equally represented
among participants with complete and incomplete (or lacking) cognitive data.
Third, the primary outcome measure was based upon a single cognitive test,
mainly investigating executive functions controlled by the frontal lobe. We have to
acknowledge that our cognitive tests, like other measurements of cognition (e.g.
the Mini Mental State Examination (MMSE), Trail-Making Test (TMT) or
Modified Telephone Interview for Cognitive Status (TICS-M) are relatively rough
measurements of cognition which may not be sensitive enough to detect changes
in cognition apparent to the patient. However, the RFFT is a reliable composite
test which is not limited by a ceiling or floor effect and thereby more sensitive to
subtle changes in cognitive performance in both young and old persons as
compared to the MMSE, TMT or TICS-M [24]. Moreover, the main findings were
confirmed using performance on the VAT. Fourth, the use of a computer database
is an imperfect measure of adherence to statin therapy. Nevertheless, we think that
pharmacy-based data are more reliable than self-reported statin therapy as used in
previous studies. Finally, the PREVEND cohort is enriched for elevated
albuminuria which could induce selection bias, as albuminuria is a risk factor for
CVD.20 However, a sensitivity analysis in a subsample representative for the
general population did not change results.
Our study has several strengths. Our population-based cohort included a wide
age range from 35 to 82 years. Moreover, the prevalence of statin use in our
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population (10%) reflects the prevalence of statin use in the Dutch population
[39]. Therefore, the generalizability of our data is probably well preserved.
Notable other strengths of our study are that participants were well phenotyped
with respect to cardiovascular risk and cognitive performance, the long follow-up
of statin use (.6 years in 15% of statin users) and the detailed data on statin use
obtained from a computerized pharmacy database. Previous studies used
dichotomized or self-reported statin use as main determinant and had shorter
durations of follow-up, although it could be argued that follow-up should be even
longer than in our study as clinically relevant cognitive dysfunction might not take
several years but several decades to develop. Finally, to our knowledge, we are the
first to report on an in-depth analysis of statin use (including type, duration and
dosage) and cognitive function in a large population-based cohort.
In conclusion, this large population-based cohort, statin use was not
independently associated with better cognitive function. Statin users with long
duration of use or high doses of statins had a similar cognitive performance as
non-users. There was no difference in results in persons with either low or high
cardiovascular risk, or in older versus younger subjects. Our findings add to the
current knowledge that neither early-life nor long exposure to statins is associated
with preserved cognitive function. In our opinion, there is no support for a
relevant therapeutic benefit of statin use on cognitive function.
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S1 Fig. Percentage of subjects with low VAT score in statin users and non-users
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